Plasmid DNA Manufacturing Market Study Explores Industry Growth Toward $7.63 Billion

The plasmid DNA manufacturing market is positioned for remarkable expansion as advancements in biotechnology continue to accelerate. Driven by increasing applications in vaccines and gene therapies, this sector is attracting significant attention from investors and industry leaders alike. Below is an overview of market value projections, leading companies, emerging trends, and segmentation details that outline the current and future landscape of this important industry.

Plasmid DNA Manufacturing Market Size and Growth Outlook
The plasmid DNA manufacturing market is expected to experience rapid growth, reaching a value of $7.64 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 20.9%. The surge is fueled by growing demand for DNA-based vaccines, escalating investments in gene and cell therapy development pipelines, and the scaling up of commercial manufacturing capacities. Additionally, the market benefits from increasing focus on regulatory-compliant production standards and the adoption of cutting-edge purification technologies. Key anticipated trends include a rise in GMP-grade plasmid DNA production, more widespread use of automated bioprocessing systems, expanded applications of plasmid DNA in gene therapy, and a steady increase in large-scale production capabilities with emphasis on high-purity DNA output.

The plasmid dna manufacturing market size has grown exponentially in recent years. It will grow from $2.89 billion in 2025 to $3.58 billion in 2026 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to increasing use of plasmid dna in research applications, expansion of molecular cloning activities, growth of preclinical therapeutic development, rising investments in biotechnology research, improved bacterial fermentation techniques.

Download a free sample of the plasmid dna manufacturing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15895&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

The Leading Players Steering the Plasmid DNA Manufacturing Market
Several prominent companies hold significant influence in the plasmid DNA manufacturing arena. These include Thermo Fisher Scientific Inc., Eurofins Genomics LLC, Catalent Inc., Charles River Laboratories, Recipharm AB, Kaneka Corp., Genscript Biotech Corporation, Aldevron LLC, Genewiz, OriGene Technologies, Celonic AG, Creative Biogene, Cellectis, Synbio Technologies, VectorBuilder Inc., Altogen Biosystems, Andelyn Biosciences, AGC Biologics, VGXI, GeneCopoeia, PlasmidFactory GmbH & Co. KG, Akron Biotech, and PackGene Biotech Inc. A notable acquisition took place in March 2023 when Sartorius Stedim Biotech, a German biotech solutions provider, purchased Polyplus for about US$2.6 billion (€2.4 billion). This deal strengthens Sartorius's plasmid DNA capabilities by incorporating Polyplus' GMP-grade plasmid DNA and transfection reagents, thereby enhancing offerings for viral vector and gene therapy production. Polyplus is a France-based firm specializing in GMP-grade plasmid DNA and nucleic acid delivery reagents for gene and cell therapy applications.

Emerging Trends Highlighting Opportunities in the Plasmid DNA Sector
Innovation is at the heart of ongoing growth in plasmid DNA manufacturing, with companies investing heavily in advanced bioprocessing technologies aimed at improving production efficiency, scalability, and quality. These technological advancements are designed to make manufacturing more cost-effective while ensuring strict adherence to regulatory requirements for therapeutic use. For example, in January 2023, Charles River Laboratories introduced the eXpDNA platform. This system is engineered to streamline the production and purification of high-quality plasmid DNA, combining scalable manufacturing processes with rigorous quality controls. The platform supports various applications including gene therapy and DNA vaccine development, meeting the high standards needed for clinical and therapeutic products.

View the full plasmid dna manufacturing market report:
https://www.thebusinessresearchcompany.com/report/plasmid-dna-manufacturing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Breakdown of Market Segments Capturing Largest Shares
The plasmid DNA manufacturing market is categorized across several segments:
1) By Grade: Research and Development Grade, Good Manufacturing Practice (GMP) Grade
2) By Development Phase: Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics
3) By Disease Focus: Infectious Disease, Cancer, Genetic Disorders, Other Diseases
4) By Application: DNA Vaccines, Cell and Gene Therapy, Immunotherapy, and Other Related Uses

Within these, the Research and Development Grade segment is further divided into small-scale plasmid DNA production and preclinical research DNA. Meanwhile, the GMP Grade segment includes clinical trial material production and commercial-scale plasmid DNA production. These subdivisions reflect the varying levels of production scale and regulatory compliance required across the development and commercialization stages.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.